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Abstract:

Anticancer drugs are prescribed and administrated to an increasing number of patients on a daily
basis. As a consequence, a number of concerns have been raised about the patient health and safety
in the case that the drugs administered are not at the required concentration or even worse not the
correct ones. Quality control of therapeutic solutions has therefore been extensively implemented
in hospital environments, in order to avoid any failure in the intense workflow faced by
administering pharmacists. In the present study, infrared (IR) and Raman spectroscopy have been
employed for the analysis of 3 commercially available therapeutic solutions TEVA®, MYLAN®,
CERUBIDINE®, respectively containing doxorubicin, epirubicin and daunorubicin. They
perfectly illustrate the analytical difficulties encountered, as these 3 chemotherapeutic drugs are
isomers, hardly distinguishable with conventional approaches such as UV/VIS spectrometry. Any
analytical failure to identify these molecules can lead to delays in patient treatment. While Partial
Least Squares Regression analysis demonstrates that both Raman and IR can deliver satisfactory
quantitative analysis in the clinical range, with respective Root Mean Square Error of Cross
Validation (RMSECV) between 0.0127 – 0.0220 g.L-1 and 0.0573 – 0.0759 g.L-1, the identification
rate between the 2 techniques differs substantially. Indeed, Principal Component Analysis –
Factorial Discriminant Analysis (PCA-FDA) highlights that, depending on the data preprocessing
applied to Raman spectra, the discrimination between the 3 drugs is decreased, with in some cases
specificity and sensitivity below 50%. However, IR analysis displays encouraging results with an
overall specificity and sensitivity between 99-100%, suggesting that reliable validation of the
therapeutic solution for administration to patients can be achieved. IR and Raman spectroscopy
could assist and support quality control of chemotherapeutic solutions prepared in personalised
concentrations for each patient. The effective and reliable characterisation of therapeutic solutions
could have a lot to offer to improve current practices in a near future.
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I. Introduction:
Evolutions of clinical procedures and protocols in recent years are motivated by improvement of
patient safety. Anticancer drugs are extensively used on a daily basis, the number of patients
treated still increasing annually. Errors in medications are the main risk leading to therapeutic
failure, which, considering the hazardous nature of most anti-cancers drugs, can have disastrous
repercussion for a patient’s health. As a result, numerous hospitals have implemented internal
regulations to standardise their own procedures and minimise the risk of erroneous treatment of a
patient. High performance liquid chromatography (HPLC) remains the gold standard for
quantitative analysis of organic compounds as part of daily quality control and is therefore one of
most commonly found methods in clinical analytical laboratories attached to preparation facilities.
Mass spectrometry is also a powerful technique for drug screening and analysis, extensively
employed in the development of new pharmaceutical compounds or patient monitoring through
detection and quantification in body fluids such as serum, urine or saliva [1, 2]. However, it is not
currently an option for therapeutic screening applications, due to time constraints of the clinical
workflow, requirements for sample preparation, and simply the cost involved. However, some
limitations such as high operating costs, relatively low output and the requirement of specialised
skills make it less than ideal for routine analysis of chemotherapy preparations [3, 4]. Flowinjection analysis (FIA) spectroscopic based methods are the most commonly implemented, with
Ultraviolet-coupled to Fourier-transform infrared spectrometry (UV/vis-FTIR) probably the most
widespread [5, 6]. Recent evolutions have seen the infrared detection replaced by Raman
technologies to overcome some of the limitations, but implementation in clinics still requires an
aliquot to be taken for injection into the analytical device [7, 8]. Moreover, investigations are
ongoing about the possibility to use Raman spectroscopy as a non-invasive tool to overcome some
current limitation such as large volume required for FIA, but mostly to avoid any risk in relation
to exposure of staff to hazardous solutions [9].
Vibrational spectroscopic techniques, both infrared (IR) absorption and Raman scattering, deliver
specific molecular fingerprinting signatures of samples. They have been extensively studied for
biomedical applications [10, 11] can be used and exploited as novel and accurate methods for
histopathology [12], cytology [13], biopsy characterisation [14], surgical guidance [15], treatment
monitoring [16] and drug studies [17]. The rapid, cost effective, label free and non-destructive
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advantages are indeed often pointed out to highlight the benefits of those techniques, but it is the
analytical capabilities in terms of both qualitative and quantitative performances are also most
relevant for a wide range of clinically oriented applications [18, 19]. IR and Raman spectroscopy
are powerful analytical tools widely used for characterisation of organic molecules such as, for
example, therapeutic drugs [20]. Although primarily used in industry and research laboratories as
screening tools to monitor whether a synthesis process has been successful [21], coupling the
molecular specificity of the spectra collected with optimised quantitative approaches strongly
promotes the techniques for therapeutic solution screening in the clinical environment [22]. In
previous studies, although encouraging results are documented for monitoring a number of
molecules such as ganciclovir [23] or 5FU [24], directly in the infusion bag, the material used for
the packaging, often polystyrene like, also has strong contributions to the spectra that can limit the
usable analytical range and lead to difficulties in quantifying and/or identifying the
chemotherapeutic drugs accurately [25]. Therefore, such developments remain only at the research
level and no translation into the clinic has been achieved as yet, suggesting that the present
workflow, entailing analysis of aliquots from the therapeutic solutions is still the most realistic
approach.
In the present study, three commercial formulations, TEVA® (Doxorubicin), MYLAN®
(epirubicin) and CERUBIDINE® (daunorubicin) have been used to evaluate the potential of Raman
and infrared spectroscopy for the analysis of therapeutic solutions in such a workflow. The
chemotherapeutic agents are chemically similar, and thus present difficulties in terms of their
identification and/or quantification with UV absorbance spectroscopy. Consequently, a
comparative study has been conducted as a demonstration of the potential of vibrational
spectroscopy as quality control tools for clinical use. A two-step approach to this demonstration
has been implemented, firstly evaluating the discriminative capabilities of both techniques,
irrespective of concentrations, by means of Principal Component Analysis (PCA) coupled to
Factorial Discriminant Analysis (PCA-FDA); and secondly determination of the precision of the
quantitative analysis of the approaches using the Partial Least Squares Analysis (PLSR).

2. Materials and Methods:
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2.1 Anticancer drugs selected and sample preparation:
The study includes three commercial anthracycline forms, TEVA® (doxorubicin, injectable
solution, 2 g.L-1), MYLAN® (epirubicin injectable solution, 2 g.L-1) and CERUBIDINE®
(daunorubicin, lyophilised powder, 20 mg) which were provided through a collaboration
established with the University Hospital of Tours. While TEVA® and MYLAN® contain small
amounts of HCl and NaOH (<1%), CERUBIDINE® has mannitol added to the formulation, in
concentrations as high as 100 mg per 20 mg daunorubicin. Mannitol is a commonly found excipient
in commercialized daunorubicin-based chemotherapeutics approved for clinical use. The UCBO
unit (Unité de Biopharmacie Clinique Oncologique, Tours, France) deals with the preparation of
anticancer drug formulations directly on site for rapid administration to patients. Based on recent
clinical protocols, a set of 8 aqueous solutions, with drug concentrations of 2 g.L-1, 1.5 g.L-1, 1 g.L1

, 0.5 g.L-1, 0.25 g.L-1, 0.125 g.L-1, 0.0625 g.L-1 to 0.03125 g.L-1, corresponding to clinically

relevant concentrations, have been prepared for each chemotherapeutic drug. The samples were
prepared from the stock solution using serial dilutions, which were analysed directly with Raman
and infrared spectroscopy. The procedure has been repeated 5 times in order to obtain 5
independent sets of spectra. All quoted concentrations refer to the amount of drug present in the
solution without taking into account excipients. All samples were prepared freshly on the day of
analysis and stored at 4°C in a dark room to avoid photo-damage prior to spectral analysis. ATRIR spectra have also been recorded for mannitol 10 g.L-1 and 0.15625 g.L-1 which correspond to
the concentrations of mannitol found in CERUBIDINE® 2 g.L-1 and 0.03125 g.L-1, respectively.

1.2 Data collection

The current work flow in place at the UCBO unit (Unité de Biopharmacie Clinique Oncologique,
Tours, France) is based on a Multipsec® analyser (MICRODOM, France). The pharmacists
receive between 100 and 150 anticancer drug solutions on a daily basis which require analysis and
clearance before they are administered to patients. For each individual sample, 1.5 mL is extracted
to an aliquot and injected in the analyser with a syringe. The protocols employed in this study for
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Raman and Infrared analysis have been derived from the current procedures and designed to
improve on the analytical performance.

1.2.1

Raman spectroscopy analysis

Raman spectra were collected using a Labram spectrometer (Horiba Jobin-Yvon, France) equipped
with a 690 nm laser source delivering ~10 mW at the sample. 500 µL of the solution were placed
in a quartz cuvette and the data was collected by illumining the sample through the wall of the
cuvette. In order to ensure maximum reproducibility between measurements, a macro sampling
holder, consisting of a cuvette holder attached to the turret of the microscope was employed.
Basically, the laser coming out of the turret is reflected by a 45° mirror and directed through the
quartz cuvette. Although the set up requires larger volumes to perform the analysis, the laser is not
tightly focused and thus the risk of any photothermal damage is minimised. The spectral range was
set between 150- 3700 cm-1, resulting in a spectral resolution of about 2.5 cm-1, achieved using a
300 lines/mm grating. Two accumulations of 20 seconds were taken for each spectrum. 5
independent sets of dilutions have been prepared for each formulation and analyzed on different
days to capture possible instrumental variability in measurements. Additionally, 5 spectra have
been measured for each concentration tested. In total, 200 spectra were recorded over the range of
concentrations for each anticancer drug included in this study.

1.2.2

Infrared spectroscopy analysis

Infrared spectra were recorded with a Frontier spectrometer (Perkin Elmer, France) equipped with
a multi-reflection (n = 10) Attenuated Total Reflectance (ATR) accessory (Eurolabo, France). The
IR spectra collected result from 16 scans performed over the range 600 – 4000 cm-1 with a spectral
resolution of 4 cm-1. A background was acquired (64 scans) and ratioed with the sample spectra
by the software. 2 μl drops were deposited directly on the diamond crystal and allowed to air dry
prior to analysis. 5 independent replicates have been measured for each concentration tested, 5
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spectra recorded each time. In total, 200 spectra were recorded over the range of concentrations
for each anticancer drug included in this study. The time required to record spectra from one drop
is about 5 mins, including drying time and data collection, which is comparable to protocols
currently employed at the Hospital of Tours.

2.2.3 Data handling:
The Raman and IR data sets have been pre-processed and analysed using MATLAB (Mathworks,
USA). For the purpose of the study, although the preprocessing and data analysis steps have been
broken down as individual procedures subsequently applied to data, one should keep in mind that
the optimised data processing and analysis protocols are easily incorporated in instrumental
software and implemented as automated functions. Once the protocol has been established, total
computational time to apply quantitative and discriminative analysis is less than 1 minute
a) Discriminative analysis: Raman spectra have been cut in order to focus on the fingerprint
region (300-1800 cm-1) in which the most relevant spectral features are observed. Pre-processing
of Raman spectra included baseline correction, using Lieber or Extended Multiplicative Scattering
Correction (EMSC), followed by vector normalisation. While the Lieber algorithm estimates the
background by a polynomial function and by an iterative method based on least squares [26], the
EMSC is more advanced approach allowing to correct for additive baseline effects, multiplicative
scaling effects, and interference effects [27]. For instance, spectra of deionised water were
provided to neutralise its contribution to the Raman spectra collected from the different solutions.
For consistency, infrared spectra have also been reduced to the fingerprint region (600-1800 cm-1)
prior to being subjected to baseline correction (rubber band) and a vector normalisation. The lower
limit of the spectral range for ATR-IR is defined by the crystal material, generating a cut-off of
the signal collected. Compared to Raman spectroscopy, ATR-IR therefore has a reduced range in
the finger print region, which is inherent to the technique. Once pre-processing was completed,
both Raman and IR spectra were analysed by PCA [28] and PCA-FDA (PCA-FactorialDiscrimination-Analysis) [29]. Although PCA is a well-established method for rapid evaluation of
the data, highlighting the spectral variability present in data sets, more advanced approaches such
as PCA-FDA are required to deliver information about the discriminative performance of the
techniques. PCA-FDA includes a 100 fold cross validation through a leave K-out cross validation
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routine. This approach ensures no replicate of a given sample can be found in both the calibration
and validation sets and avoids over optimistic outcome of the quantitative analysis [30]. 1/3 of the
data is selected as a test set, while the 2/3 of the remaining samples were used as calibration and
validation sets. The test set is kept constant and at each iteration, different combinations of
randomly selected calibration/validations sets are tested. Ultimately, the results are presented in
the form of confusion matrices, allowing calculation of the specificity and sensitivity of the
discrimination analysis performed.
b) Quantitative analysis: Normalisation procedures should be avoided to preserve the
intensity to concentration relationship in the data. Therefore, only an offset correction has been
applied for the spectra pre-processing. PLSR remains the most relevant analysis to evaluate the
possibility of performing quantitative analysis of systematically varying vibrational spectra [31,
32]. It is a supervised multivariate technique that is highly specific for quantitative methods, and
is usually performed via two steps: calibration and validation. Therefore, similarly to the PCAFDA a 100 fold leave K-out cross validation was implemented. The output of PLSR provides
performance criteria defined under the linearity (R2) and precision, also called Root Mean Square
Error for Cross Validation (RMSECV). Additionally, the lower Limit Of Detection – lower LOD)
has been estimated based on the work published by Allegrini and al

3. Results and Discussion
3.1 UV characterisation of anthracycline formulation
Anthracyclines are a group of cytotoxic compounds used as treatment of a wide variety of cancers,
from leukemia, thyroid, lung and other neoplasia, ovarian, breast, lung and gastric cancer [33]
leading to a large number of solutions being prepared on a daily basis for patients under
chemotherapeutic treatment. Doxorubicin, epirubicin and daunorubicn are composed of
tetracycline aromatic moiety attached to a sugar moiety of daunsamine via a glyosidic bond. As
displayed in Figure 1, these 3 anthracyclines have the same aromatic chromophore and the
difference between them concerns the side chains. Notably, epirubicin is a stereoisomer of
doxorubicin, and differs from it only in the orientation of the hydroxyl group of the hexapyranosyl
sugar [33]. Daunorubicin differs from doxorubicin only in the shorter side chain terminated with
a methyl group instead of a primary alcohol group. As a direct consequence, those molecules
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cannot be discriminated using UV spectrophotometry. The absorbance spectra were collected for
the 3 molecules in their commercial forms (doxorubicin from TEVA®, epirubicin from MYLAN®
and daunorubicin from CERUBIDINE®. These spectra have the same profile, with the two main
maxima located at ca. 480 and 500 nm. NaOH, HCl and mannitol (a sugar) present in the
commercial forms do not have direct contribution to the UV/Vis spectra in this range, and thus the
absorbance is solely derived from the drugs. While quantitative analysis is expected to be
achievable with UV absorbance spectroscopy, difficulties to perform specific identification of the
chemotherapeutic drugs are understandable. As they contain information of all the moieties of the
molecule, rather than just the chromophoric π-conjugated structures, vibrational spectra are richer
in specific molecular structural information than UV-vis absorption spectra. This study aims to
demonstrate this and optimise protocols to implement the analysis in a clinical workflow.

Doxorubicin

Epirubicin

Daunorubicin

Figure 1: Chemical structures of the 3 anticancer drugs of interest.

3.2. Quantitative and discriminant analysis using Raman spectroscopy
3.2.1. Raman characterisation of anthracycline formulations
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Figure 2: Mean macro-Raman spectra recorded from TEVA® (a), MYLAN® (b) and
CERUBIDINE® (c) commercial forms diluted to drug concentrations of 2g.L-1 in deionised
water; deionised water (d) and manitol solution at 10 g.L-1 in deionised water (e). Spectra are
offset for clarity.
Figure 2 presents mean Raman spectra collected from the commercial forms of the three
chemotherapeutic drugs, TEVA® (spectrum a), MYLAN® (spectrum b) and CERUBIDINE®
(spectrum c) diluted to concentrations of 2 g.L-1 in deionised water. As expected, due to their
similar chromophores, spectral signatures display strong similarities, all major peaks being found
in all 3 formulations. To further represent the vibrational modes observed, Table 1 provides a direct
comparison of their positions with corresponding assignments. The differences observed are
relatively minor, especially for TEVA® (spectrum a) vs MYLAN® (spectrum b), which show
only a 2 cm-1 shift between 1089 cm-1 vs 1091 cm-1. With the exception of the band at 886 cm-1
observed in the case of CERUBIDINE®, all other features appear consistent for the 3 molecules,
as seen in Figure 2. Moreover, the recording of Raman spectra from liquid samples can lead to
some underlying contribution from water. Although the Raman bands observed have strong
intensities, the profile of the signal and the band around 1600-1650 cm-1 (Figure 2) suggest that
H2O (spectrum d) also contributes to the spectra of the drug solutions. The features observed
around 450 cm-1 and 1300 cm-1 in the water spectrum are respectively assigned to the quartz cuvette
and the glass of the focusing lens of the macro adapter used. In comparison to the short side chains,
the intensity of the peaks associated to the conjugated chromophores is dominant, due to their high
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Raman activity. Consequently, no major spectral differences can be observed between the 3
formulations. Moreover, in contrast, molecules such as NaOH and HCl do not have any significant
contribution to the spectra. In the solution of 2 g.L-1 CERUBIDINE®, mannitol is found at 10 g.L1

. Despite the relatively high concentration, the Raman spectrum collected from the mannitol

aqueous solution does not exhibit strong features, and the only difference with the water spectrum
is at 886 cm-1, where a weak peak arises from the broad background (spectrum 2e).

Table 1: Bands assignments of main features observed in the finger print region of TEVA®,
MYLAN® and CERUBIDINE® Raman spectra collected from 2 g.L-1 solutions in deionized water
[33-37].
TEVA®
(cm-1)

MYLAN®
(cm-1)

CERUBIDI
NE® (cm-1)

Assignments

355

350

351

-

446

446

447

-

-

886

1000

1000

998

C-C stretching of alicyclic ring

1089

1091

1091

Ring breathing and aromatic C-H bending
vibrations, methoxy C-O stretching and CC aliphatic chain vibrations

1219

1219

1219

C-O-H vibrations and in plane bending of
O-H

1250

1250

1251

C-O vibrations

1309

1309

1311

C-O-H vibrations

1445

1445

1453

Aromatic ring stretching modes

1582

1582

1586

Aromatic ring stretching

1647

1647

1650

Hydrogen bonded stretching vibrations of
C=O

C-C-O vibrations
deformation

,

C=O

in

plane

-
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3.2.2 Discriminant analysis using PCA-FDA
Discriminant and quantitative analysis are two aspects of the data mining process not necessarily
achieved through similar approaches, although they remain strongly connected. One could
consider that any measurements of concentrations performed cannot be validated without
identifying the molecule in solution being analysed. Therefore, it appears to be more relevant to
first identify the drug and then aim for the quantification. While the quantitative analysis can
establish a correlation between the intensity of the signal and the concentrations measured, when
it comes to discriminating data sets based on the molecular information of the spectra, the overall
intensity should be disregarded in favour of band positions, number and intensity ratios.
Consequently, in the present study, it has been considered more relevant to subject the spectra to
both baseline correction and vector normalisation prior to PCA-FDA. Thus, the concentration
parameter has been removed from the analysis, focusing solely on the variations described above.
Moreover, two methods for baseline correction have been evaluated, the Lieber correction [38]
and EMSC [39].
PCA is a well-established unsupervised approach for rapid evaluation of spectral variability in
complex data sets. Intensively used for analysis of IR and Raman spectra collected from biological
samples, it readily allows visualisation of possible discrimination of samples using scatter plots
[40, 41]. Figure 3A displays the scatter plot obtained for Raman spectra collected from 2 g.L-1
TEVA®, MYLAN® and CERUBIDINE® subjected to Lieber baseline correction followed by
vector normalisation. Although spectral differences are not conspicuous after preprocessing, the
scatter plot presents three well separated groups, corresponding to each formulation. It can be seen
that, according to Principal Component 1 (PC1), spectra collected from CERUBIDINE® are well
separated from the others (Figure 3A red cluster), while TEVA® and MYLAN® data are only
discriminated according to Principal Component 2 (PC2) (Figure 3A blue and green clusters).
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Figure 3: PCA of Raman data collected from TEVA® (blue), MYLAN® (green) and
CERUBIDINE® (red) 2 g.L-1 solutions in deionised water. A and B: scatter plot of PC1 and PC2
with corresponding loadings 1 and 2 obtained from data subjected to Lieber baseline correction
and vector normalization; C and D: scatter plot of PC1 and PC2 with corresponding loadings 1
and 2 obtained from data subjected to EMSC correction and vector normalization. Loading are
offset for clarity.

The loadings corresponding to each PC are displayed in Figure 3B, highlighting the spectral
features leading to the distribution of the data points in the scatter plot. Dominant features in the
loading of PC1 observed at 447 cm-1, 891 cm-1, 1096 cm-1, 1221 cm-1, 1263 cm-1 and 1301 cm-1,
1411 cm-1, 1472 cm-1 and 1641 cm-1 correspond to dominant peaks previously identified in the
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mean spectra (Table 1). Loading 2, only accounting for 4.4% of the explained variance
discriminating TEVA® (blue) and MYLAN® (green), displays a lower number of strong features
(357 cm-1, 475 cm-1, 1210 cm-1, 1306 cm-1, and 1448 cm-1). These 2 forms are really similar with
only NaOH and HCl as excipients which have no contribution to the spectral signatures recorded.
The features of the loading of PC2 are common to the Raman spectra of both compounds, as shown
in Figure 2, but the differentiating features suggest that small shifts can result from the different
stereo-chemistry of the molecules.
Although PCA performed using a single concentration (i.e. 2 g.L-1) exhibits clear separation of the
three clusters and thus possible identification of the different chemotherapeutic forms, it is also
important to address the need to perform discriminant analysis as an overall classifier, including
all concentrations. The spectra in Figure 2 illustrate how similar the Raman spectra of the three
formulations are, and the PCA in Figure 3 indicates that any variations between them are minor
differences in peaks positions and intensities. Applying PCA to the range of possible combinations
of concentrations would require considerable effort, and thus other multivariate approaches such
as PCA-FDA need to be implemented. All the different concentrations and drug types have been
considered as distinct groups to classify (n = 24). The approach is supervised and implementation
of a cross validation procedure is necessary to ensure the robustness of discrimination observed.
Specifically, 1/3 of the data was used as a validation set and for each iteration of the 100-fold leave
K-out cross validation, calibration and validation sets were constituted from the 2/3 of the
remaining spectra. To better appreciate the specificity and sensitivity of the discrimination, at each
iteration of the cross validation, results obtained with a model based on 4 principal components
are reported in a confusion matrix (Table 3). This step of the analysis aims purely to discriminate
the different anti-cancer drugs without any significance given to their concentrations. Therefore,
successful classification was judged solely on the ability to identify the correct drug corresponding
to the test spectra, irrespective of the concentration assignment. Although the overall specificity
and sensitivity obtained are above 90%, the results are concentration and molecule dependent, and
in some cases exhibit rather low values, as for example the TEVA® S7 (specificity = 85%),
MYLAN® S1 (specificity = 75%) or CERUBIDINE® S1 (sensitivity 50%) (Table 3).
Although the results are encouraging, observation made in Figure 2 of minimal spectral differences
between TEVA® and MYLAN® formulations, the specificity of the classification achieved is
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somehow surprising. Raman spectroscopy is a technique particularly sensitive to changes of the
light scattering when performing analysis on liquid samples. While the dynamic range of
concentrations tested could lead to inconsistencies in the measurements, solutions of commercial
formulations also contain excipients which possibly contribute to the spectra collected, not
necessarily in terms of spectral features considering the concentrations, but rather affecting the
baseline (or background) through scattering [42]. For this reason, more advanced baseline
correction, taking into account the water spectrum has been performed by means of EMSC coupled
to vector normalisation prior to PCA (Figure 3C and D). While the scatter plot from the PCA still
displays clear separation between data groups according to formulation (Figure 3C), the
corresponding loadings of PC1 and PC2 are strongly affected, and retain only residual features at
895 cm-1,
918 cm-1, 993 cm-1, 1096 cm-1, 1180 cm-1, 1265 cm-1, 1471 cm-1. Clearly, a standard baseline
correction does not take into account the changes in band ratios induced by underlying background
in the spectra possibly leading to misinterpretation of results. Following EMSC, both the residual
water and background are removed and relative band intensities are more accurately corrected.
Consequently, when performing the PCA-FDA, the outcome is also affected and the overall
specificity and sensitivity are now found to respectively be between 64.4% - 72.5% and 53.3% 59.2% with the classification model constructed using 3 principal components (Table 4). A number
of concentrations exhibit values below 50%, which indicates that a non-negligible number of misclassifications have occurred, thus raising some serious concerns about the choice of data
preprocessing having high impact on the analysis outcome and consequently the robustness of
Raman spectroscopy measurements for drug identification can be questioned. In some cases, such
as TEVA® S3 and CERUBIDINE® S4, there is obviously a reduced reliability in the drug
identification, which for high concentrations can generate higher risks of dose intoxication of
patients. Moreover, at lower concentrations, the accuracy is also not suitable for accurate
classification, suggesting the specificity of Raman is not sufficient. EMSC is an advanced
correction method able to remove instrumental and/or experimental interferences. However,
despite applying such correction, the outcome of the PCA-FDA remains quite disappointing,
suggesting that the sensitivity and specificity observed are directly linked to the ability of the
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technique to discriminate the 3 therapeutic solutions rather than the underlying source of
variability.

Table 3: Specificity and sensitivity % of PCA_FDA for Raman data processed without EMSC.

Table 4: Specificity and sensitivity % of PCA_FDA for Raman data with EMSC.

3.2.3 Quantitative analysis using PLSR
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Figure 4: Mean Raman spectra of the finger print regions collected from TEVA® following
serial dilutions. Corresponding drug concentrations are 2g.L-1 (blue), 1.5g.L-1 (red), 1g.L-1
(green), 0.5 g.L-1 (yellow), 0.25g.L-1(black), 0.125 g.L-1 (cyan), 0.0625 g.L-1 (magenta), 0.03125
g.L-1 (grey), water (violet). Spectra are offset for clarity.

While examination of spectra allows identification of the anti-cancer drug with a reasonably high
degree of accuracy, the linear relationship existing between the intensity of the peaks and the
concentrations prepared can be examined and used as a quantitative prediction model using PLSR.
Due to the experimental macro set up used in this study, the reproducibility achieved during the
measurements enables unambiguous monitoring of the decrease of the peak intensities according
to the dilutions performed, as illustrated for the example of TEVA® in Figure 4. PLSR is a reliable
method to evaluate the quantitative information contained in the data sets collected. However, in
order to ensure maximum statistical relevancy, cross validation procedures are generally
implemented [30], in order to demonstrate that the analysis is not biased, but also to test the
robustness of the predictive model used. Considering the size of the number of spectra available
for each concentration, a 100-fold leave K out cross validation with 2/3 of spectra used as
calibration and the remaining 1/3 as validation has been preferred for this study. The calibration
and validation are therefore completely independent and selected randomly at each iteration of the
cross validation, enabling testing of numerous data combinations. The first graph generated during
the analysis represents the Root Mean Square Error of Calibration (RMSEC) according to the
number of dimensions used to regress the data (Figure 5A). As a supervised method, and aiming
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to deliver the lowest RMSEC and thus the best precision, a gradual decrease towards 0 is expected
as the number of dimensions employed in the model increases. Once the model has been
established using the calibration set, it is then evaluated with the validation spectra. The Figure 5B
exhibits first a steep decrease in the RMSECV (validation) before slightly increasing a stabilizing
around 0.015 g.L-1. All dimensions calculated from the calibration set are not relevant to the
quantification, and according to Figure 5B, above 3 dimensions over fitting of the data could
actually affect the precision of the predictive model. Consequently, the regression plot has been
implemented using three dimensions, and is presented in Figure 5C. The correlation between
observed concentration (true concentrations) and predicted concentrations (experimental
concentrations) delivers a linear trend characterised by R2 value of 0.9997 (Table 5). The error
bars illustrate the standard deviation calculated from the 100 fold cross validation and further
support the high reproducibility of the measurements. The overall RMSECV reached was found
to be 0.0127 g.L-1 for TEVA® (Table 5). The numbers of dimensions used to construct the PLSR
predictive models, respectively 3, 5 and 5 for TEVA®, MYLAN® and DNR, are also indicated in
Table 5. Figure 5D shows the weighting vector corresponding to the PLSR analysis performed on
TEVA® solutions. It represents the wavenumbers used to construct the predictive models,
confirming the molecular specificity of the analysis has been preserved. The features with major
contribution in the PLSR model can be found at 354 cm-1, 445 cm-1, 1000 cm-1, 1090 cm-1, 1219
cm-1, 1249 cm-1, 1309 cm-1, 1453 cm-1, 1581 cm-1, 1647 cm-1 which are the major spectral features
previously observed in Figure 3 and Table 1. Finally, a similar approach has been employed for
MYLAN® and CERUBIDINE® formulations, yielding respective RMSECV of 0.0173 g.L-1 and
0.0220g.L-1, as summarised in Table 5. Although inconsistent between patients and hospital, the
lowest administered concentration for doxorubicin is roughly 0.15 g.L-1, and therefore the
corresponding RMSECV found of 0.0127 g.L-1 suggest overall imprecision of about 8.5%.
Similarly for MYLAN® and CERUBIDINE®, the RMSECV respectively account for 5.8% and
2.35% compared to the lowest doses typically prescribed (0.3 g.L-1 and 1.2 g.L-1). The lower limit
of detection (LOD) calculated from the PLSR analysis indicates that Raman spectroscopy can pick
up concentrations as low as 0.0290 g.L-1, XXX g.L-1 and XXX g.L-1 for respectively TEVA®,
MYLAN® and CERUBIDINE® which are all more than 10 times below the lowest dose
administered to patients.
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Figure 5: PLSR analysis performed on TEVA®. A: Standard deviation error of calibration; B:
Standard deviation error of validation; C: Regression fitting and D: Weighting vector. Error
bars represent the standard deviation

Table 5: PLSR results obtained from the 3 chemotherapeutic drug solutions tested
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3.3. Discriminant and quantitative analysis using ATR-IR spectroscopy
3.3.1. ATR-IR characterisation of anthracycline formulations

Figure 6: Mean ATR-IR spectra recorded from TEVA® (A), MYLAN® (B), CERUBIDINE® (C)
formulations and Mannitol (D). All spectra were recorded from solutions with final
concentration of anticancer drugs at 2g.L-1. Spectra are offset for clarity.

Although recent work has supported the feasibility to perform IR quantitative analysis with ATRIR from liquid samples [32, 43], in the present study the anti-cancer drug concentrations involved
are not sufficient to overcome the strong contribution of the water bands, which completely swamp
the features of interest (data not shown). Consequently, air drying of samples following deposition
onto the ATR crystal is required to collect exploitable data. Figure 6 displays the fingerprint region
of mean spectra collected from the 3 different formulations. TEVA® and MYLAN® (Figure 6 A
and B) deliver spectral signatures with high degree of similarity, but comparison of the peaks
positions would suggest some variations in the range 700-1200 cm-1 can be observed (Table 6).
Interestingly, the major difference compared to Raman spectroscopy is the weaker contribution of
conjugated chromophores in the signatures collected. Consequently, other contributions from side
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chains and excipients can be somehow enhanced and more easily detected. For instance, the
CERUBIDINE® mean spectrum differs from the other two without any possible ambiguity. This
can be explained by the presence of a high amount of mannitol in the formulation, obviously
delivering strong features in the IR signature (Figure 6d). Summarised in Table 6, the most intense
mannitol features at 1454 cm-1, 1085 cm-1, 1023 cm-1, 875 cm-1, 932 cm-1 and 890 cm-1 clearly
dominate in the spectrum. However, a comparison between the IR spectrum collected from
CERUBIDINE® (Figure 6c) and the pure spectrum of mannitol highlights that, despite the lower
band intensities, specific contributions from daunorubicin can be identified at 1712 cm-1, 1617 cm1

, 1582 cm-1, 1411 cm-1, 1202 cm-1, 1110 cm-1, 996 cm-1 and 984 cm-1.

Table 6: Bands positions and assignments in ATR_IR spectra collected from TEVA®, MYLAN®
and CERUBIDINE®.
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3.3.2 Discriminant analysis using PCA-FDA
Similar to Raman spectra, observations based on PCA enable a rapid visualisation of the spectral
variability contained in the data set collected by ATR-IR. While Raman spectra from liquid
samples can to some extent be affected by underlying background, the collection of infrared
spectra using the ATR set up coupled to air dried drops drastically reduces any distortion of the
baseline. Although recording of IR spectra from biological material such as cell or tissues in
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transmission can lead to Mie or resonant Mie scattering effects [44], direct deposition of the
solution on the ATR crystal minimises such phenomena. Consequently, only some offset in the
data collected is observed according to the concentrations analysed, but such effects are easily
compensated by implementation of a simple straight baseline subtraction such as the rubber band
employed here. A rubber band correction with only 2 nodes at 1800 cm-1 and 600 cm-1 has the
effect of bringing the spectral baseline down to 0 across the spectral range. Prior to performing the
discriminant analysis, the concentration parameters have been removed using a vector
normalisation to rescale all spectra.
The PCA scatter plot displays strong separation of the three formulations according to PC1 and
PC2, accounting respectively for 98.7% and 0.82% of the explained variance (Figure 7A).
Similarly to Raman spectra, PC1 unambiguously differentiates TEVA® (Figure 7A blue) and
MYLAN® (Figure 7A green) formulations from CERUBIDINE® (Figure 7A red). The
corresponding loading suggests that PC1 is basically the spectral signature of mannitol, which is
expected due to the strong features observed in the spectra of CERUBIDINE®. Notably, the bands
at 1454 cm-1, 1085 cm-1, 1022 cm-1, 931 cm-1 and 717 cm-1 support this statement. PC2
discriminates TEVA® (Figure 7A blue) from MYLAN® (Figure 7A green). The PCA tends to
maximise the explained variance expressed by the first principal components. As a consequence
of the strong contribution from the features assigned to mannitol, PC2 only accounts for 0.82%.
This observation supports the presence of small variations in bands positions as previously
witnessed and reported in Table 6. The features of loading 2 confirm that the discrimination is
based on the differing spectroscopic profiles of the compounds but due to the scattering of
CERUBIDINE® data points over the 2 other clusters in that dimension, it is unclear the
discrimnation is genuine and peaks observed specific. Pairwise PCA is the most direct and
unambiguous analysis to highlight the presence of discriminative wavenumbers between 2 datasets
[28]. Figure 7C and 7D displays respectively the scatter plot and loading 1 for the PCA applied to
TEVA® and MYLAN®. In absence of the CERUBIDINE® and associated strong mannitol bands
the scatter plot naturally reorient itself to display a clear separation of TEVA® and MYLAN®
along PC1 with an explained variance of 91.8%. The loading 1 corresponding to PC1 exhibits a
quite large number of features but interestingly some of most intense located at 767 cm-1, 1014
cm-1, 1060 cm-1, 1123 cm-1, 1212 cm-1, 1576 cm-1, 1615 cm-1 and 1719 cm-1 are either matching or
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closely related to features found in TEVA® and MYLAN® as listed in Table 6. Despite, pairwise
PCA is a relevant approach to investigate inter and intra data sets variability, it becomes relatively
difficult to evaluate all combinations of data and estimate the discrimination rate when the number
of samples is increasing. Therefore, more advanced methods such as PCA-FDA can be used.
The outcome of the PCA-FDA obtained using 3 principal components is presented in Table 7,
whereby, once again, the specificity and sensitivity has been calculated for each concentration
analysed and for each drug. Using the ATR-IR spectra for discriminative analysis leads to high
rates of correct classification with overall values equal or above 99.4%. A more detailed
breakdown of the results shows that only the lowest concentrations tested, corresponding to
0.03125 g.L-1, do not deliver 100% specificity and sensitivity for all 3 formulations. However,
with 90% as the lowest outcome, the results remain quite satisfactory for accurate and reliable
identification of formulations tested in respective formulations.

Figure 7: PCA of ATR_FTIR data collected from chemotherapeutic solutions at 2 g.L-1. A:
Scatter plot of PC1 and PC 2 with TEVA® (blue), MYLAN® (green) and CERUBIDINE® (red).
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B: Loading corresponding to PC1 (a) and PC2 (b). C: Pairwise PCA of ATR_FTIR from TEVA®
(blue) and MYLAN® (green) and D: Loading corresponding to loading PC1

Table 7: Specificity and sensitivity % of PCA_FDA for ATR_FTIR.

Considering the strong sugar features in the IR spectra collected from CERUBIDINE® it is
obvious mannitol plays a major role in the discrimination. Despite, the main concern of the study
is to investigate discrimination of solutions rather than solely the anticancer drugs, one could ask
about the specificity of the analysis to actually differentiate the therapeutic solution containing
CERUBIDINE® from pure solution of mannitol. This can be demonstrated thanks to a pair wise
PCA performed from CERUBIDINE® solution at 0.03125 g.L-1, the lowest concentration
presently tested, and mannitol solution at 0.15625g.L-1. The concentration of mannitol has been
adjusted accordingly to the dilution factor of the stock solution of CERUBIDINE®. The scatter
plot displayed in figure 8A exhibits a clear separation of the data along PC1 with 85.4% of the
explained variance. Naturally, in a pair wise PCA the PC2 with 6.5% represents the intragroup
variability. Loading 1 compared to the pure spectrum of mannitol highlights that a numerous
spectral features are affected in presence of other molecules such as daunorubicin in the solutions.
Therefore, the discrimination of CERUBIDINE® observed in the PCA-FDA is a combined
contribution of both mannitol and other ingredients including the anticancer drug. Similar

25

observation are made with all concentrations included in this study (data not shown) which is
perfectly understandable as the mannitol/daunorubicin ratio remains identical for all samples due
to the same dilution factor applied during the preparation.

Figure 8: PCA of ATR_FTIR data collected from CERUBIDINE® 0.03125 g.L-1 and Mannitol
0.15625g.L-1. A: Scatter plot of PC1 and PC 2 with CERUBIDINE® (red) and Mannitol (blue). B:
Reference spectrum of mannitol (a) and loading corresponding to PC1 (b). Spectra offset for
clarity.

3.3.3 Quantitative analysis using PLSR
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Figure 9: Mean Raman spectra of fingerprint regions of TEVA® following serial dilutions.
Spectra are organised as decreasing concentrations from the top to bottom, respectively
corresponding to doxorubicin concentrations of 2g.L-1 (red), 1.5g.L-1 (green), 1g.L-1 (blue), 0.5
g.L-1 (yellow), 0.25g.L-1 (black), 0.125 g.L-1 (magenta), 0.0625 g.L-1 (cyan), and 0.03125 g.L-1
(grey). Spectra are offset for clarity

Observation of the ATR-IR spectra collected from a set of TEVA® solutions highlights that the
intensity of the absorbance tends to decrease according to concentration (Figure 9). It has been
demonstrated that, while ATR-IR measurements can be used for quantitative analysis, the
approach has a limited range of concentrations over which the Beer- Lambert law can be directly
applied, whereby high concentration samples lead to a plateau effect with a loss of the linear
relationship [43]. As the concentration increases, the thickness of the deposited residue film
increases, to the extent that is comparable to the spatial extent of the evanescent field of the ATR.
This can be accounted for by additional dilution of the higher concentrations. However, in the
present study, it appears the dynamic range of concentrations is within the range of linearity of
absorbance response. Similar to the case for Raman, the ATR-IR spectra have been subjected to
PLSR analysis in order to evaluate how well correlated the spectral variations are with the
concentration of the anticancer formulations. Figure 10 presents the different steps performed on
the TEVA® form, as described previously in section 3.2.3. As observed with the Raman, the
weighting vector extracted from the PLSR analysis is almost an identical copy of the mean spectra
presented in Figure 10D, once more illustrating the molecular specificity of the analysis performed.
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However, the behaviour of the RMSECV according the number of dimensions included in the
analysis strongly differs compared to the Raman analysis. It tends to gradually decrease, with no
clearly defined optimal number of dimensions which would ensure no overfitting of the model.
Examination of the latent variables suggests that only the first 3 exhibit strong relevant features,
while subsequent ones become increasingly dominated by noise and random bands. Therefore,
considering the limited number of data in this investigation, it was deemed preferable to limit the
number of dimensions to 3, in order not to deliver over optimistic results for the ATR-IR analysis.
Ultimately, the outcome of the PLSR analysis delivers RMSECV higher than those observed with
Raman spectroscopy, respectively 0.0558 g.L-1, 0.0573g.L-1 and 0.0759 g.L-1 for TEVA®,
MYLAN® and CERUBIDINE® formulations (Table 8). Nevertheless, with R2 values all above
0.99, the high degree of linearity in the PLSR model constructed with the IR data is demonstrated.
However, although a multi-reflection crystal has been used, compared to the macro set up for the
Raman experiments, the repeatability in the IR analysis remains lower, leading to loss of precision.
In order to avoid over fitting of the results, the number of dimensions has been limited to 3 for the
3 drugs. Ultimately the results demonstrate the limited quantitative capabilities of the approach
when applied to anticancer formulations. For instance, the LOD calculated from the PLSR analysis
are considerably higher than for Raman analysis. With LOD of 0.5802g.L-1 (TEVA®), XXX g.L1

(MYLAN®) and XXX g.L-1 (CERUBIDINE®) uncertainties in determination of the lowest

concentrations question the reliability of ATR-IR for accurate quantification.
The Beer Lambert law is commonly employed to describe the linear relationship between
concentration of an analyte in solution and its absorbance, facilitating quantitative analysis. When
performing analysis of liquid samples, it is easy to comply with the basic requirements of uniform
optical path length of the samples and sample homogeneity, to produce reliable results. Air drying
the samples onto the ATR crystal inevitably raises questions about the uniformity and repeatability
of the sample thickness, but also the risk of heterogeneous distribution and therefore sampling in
multicomponent samples [45]. In recent years, concerns over the so-called “coffee ring effect”
have been raised, in relation to ATR FTIR analysis of dried droplets. The effect refers to the
tendency of molecular species to accumulate at the edge of the drop during the dry process [4344]. Depending on the sample concentration, the coffee ring effect can also lead to complete loss
of the signal simply because the sample accumulates outside the area of measurement of the ATR
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crystal [41]. Different types of crystals are commercially available, defined by the material of the
crystal (for example diamond or germanium) but also the number of internal reflections.
Importantly, the size of the crystal is also different and while a single reflection accessory delivers
no signal from chemotherapeutic solutions analysed, due to this coffee ring effect (data not shown),
the multi-reflection diamond crystal used in the present study offers a wider area for collection
thus enabling the 2µL to be completely deposited within the recording area. However, although
the multi-reflection accessory partially solves the limitation due to coffee ring effect, the
heterogeneity of the samples after drying remains quite high, possibly also related to the precision
of manual deposition of small volumes.

Figure 10: PLSR analysis performed on TEVA®. A: Standard deviation error of calibration; B:
Standard deviation error of validation; C: Regression fitting and D: Weighting vector. Error bars
represent the standard deviation
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Table 8: PLSR results obtained from the 3 chemotherapeutic solutions tested

Overall discussion

Direct comparison between infrared and Raman spectroscopy has been conducted for the
identification and quantification of 3 anthracyclines (TEVA®, MYLAN® and CERUBIDINE®)
in solution, at clinically relevant concentrations (i.e. in the range of concentrations administered
to patients). Data mining of spectral data sets with the help of multivariate analysis demonstrates
that discrimination of drugs and predicting concentrations can be achieved with both techniques,
although with different reliabilities. On the one hand, Raman spectroscopy displays the best
precision for quantitative analysis, with RMSECV between 0.127-0.220 g.L-1 obtained from PLSR
analysis, while on the other hand IR spectroscopy delivers higher sensitivity and specificity (above
95%) for drug identification with PCA-FDA. Both techniques behave differently due to differences
in the intrinsic nature of the signal collected. Raman spectroscopy is strongly dependent on
polarisability of the molecules which, in the case of TEVA®, MYLAN® and CERUBIDINE®,
results in spectra clearly dominated by contributions from the conjugated ring structures. In
contrast, IR is sensitive to small variations in side-chains but also to additives. Commercial
chemotherapeutic solutions are formulae or mixtures with different degrees of complexity,
depending of the number of ingredients present. While usually the drug is the most concentrated
chemical constituent of the solution, by many orders of magnitude, resulting in little or no
contribution from the other constituents, in some cases the presence of a specific molecule in
higher concentrations can change the balance and generate additional features in the spectral
signatures. In CERUBIDINE®, for example, the presence of mannitol contributes significantly to
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the profile of the infrared spectra, which are therefore representative of mixed contributions of the
drug and the sugar used as additive. This does not represent a limitation of the technique, but rather
a strength of ATR-IR compared to Raman, as manifest in the significantly improved discriminative
power of the technique resulting in higher sensitivity in classification. Some ingredient or additive
signatures, once combined with the spectral bands of the drug, can play the role of spectral markers
for more reliable identification of the stock solution used to prepare the diluted solution. In the
present study, TEVA®, MYLAN® and CERUBIDINE® are the one and only brand used for
respectively doxorubicin, epirubicin and daunorubicin. Thus the spectral bands identified and used
for discrimination will be reproducible and consistent over time. At present, quality control
laboratories in hospitals typically employ flow injection analysis which is able to deliver accurate
quantification for the majority of the 100+ solutions tested daily. The technique lacks the required
specificity, however, when challenged with the discrimination of isomers such as TEVA®,
MYLAN® and CERUBIDINE®, which display similar absorbance in the visible range, which can
result in significant delays in administration of the solutions on a daily basis. As an augmentation
to the current workflow, ATR-IR provides a potential solution for the rapid differentiation of the
solutions. Performing the ATR analysis requires small volumes (few µL) compared to other
current systems with injection of aliquots of at least 1.5 mL necessary. Considering the whole
process of data analysis can be automated and completed in less than 1 minute, the overall time to
get the result does not exceed 5 mins, which is comparable to systems already in use. Ultimately,
ATR-IR spectroscopy is a cost effective technique with compact bench top apparatus that does not
represent a huge capital investment and are increasingly user friendly, such that the data
preprocessing and analysis routines can be easily incorporated into the instrument software and
implemented in an automated protocol.

4. Conclusion
Both Raman and Infrared spectroscopy are valuable analytical tools with demonstrated potential
for clinical applications. Although often proposed as complementary, instrumental set up would
have a strong influence of their performance to a given application. The quantitative analysis of
chemotherapeutic drugs can be achieved in solution with Raman spectroscopy or following air
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drying with ATR-IR. In contrast, the discrimination of anthracyclines such as TEVA®
(doxorubicin), MYLAN® (epirubicin) and CERUBIDINE® (daunorubicin) as part of quality
control of therapeutic solutions suggests specificity of Raman analysis is more limited than that of
IR. Although air drying is required for IR, analysis results are promising and enable both
identification and quantification of all 3 molecules tested. With specificity and sensitivity above
95%, ATR-IR spectrophotometry appears to be the most valuable approach to address current
needs for discrimination of therapeutic solutions containing isomeric drugs and should be
positioned as a highly relevant technique. Having an ATR just beside on the bench as a
complementary tool to current techniques could provide an unambiguous identification in 5 mins.
To summarise, ATR-IR spectrophotometry remains a cost effective, rapid and user friendly
method which with optimization of methods would lead to fast implantation in the hospital routine.
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